The U.S. Food and Drug Administration announced on February 6, 2026 that it would issue a warning letter to firms marketing unauthorized copies of Novo Nordisk’s Wegovy semaglutide, citing violations of federal drug laws. FDA Commissioner Marty Makary said the agency would take swift action against companies mass‑marketing illegal copycat drugs that claim to be similar to FDA‑approved products.
The warning targets companies that have been selling compounded semaglutide at heavily discounted prices. Hims & Hers, a direct‑to‑consumer health platform, has been offering a compounded Wegovy alternative for $49 per month, compared with Novo’s $149 monthly price. The FDA had previously warned Hims & Hers in September 2025 about misleading marketing claims for its compounded semaglutide, but the February 6 letter escalates the enforcement.
Novo Nordisk has warned that the compounded versions are siphoning off a significant share of its U.S. obesity‑drug market and eroding its pricing power. The company’s 2026 sales guidance already reflected a decline in growth due to competitive pressures, and the FDA’s action is intended to protect Novo’s brand integrity and the safety of the drug supply chain.
The warning letter is the first step in a potential enforcement sequence that could include seizure of products, injunctions, and civil or criminal penalties. The FDA emphasized that it cannot verify the safety, efficacy, or quality of non‑approved compounded drugs, and that the agency will pursue legal action if companies continue to market them as alternatives to FDA‑approved products.
The regulatory move comes amid intensifying competition in the GLP‑1 market. Eli Lilly’s tirzepatide and other competitors are already challenging Novo’s market share, and the availability of cheaper compounded alternatives could accelerate price pressure across the sector. State‑level legislation is also moving toward tighter regulation of compounding pharmacies, potentially creating a patchwork of rules that could further constrain the business model of companies like Hims & Hers.
Novo Nordisk CEO Mike Doustdar dismissed the $49 compounded pill as a “waste of money,” citing the proprietary SNAC absorption technology that makes oral Wegovy effective. Novo spokesperson Ambre James‑Brown called the compounded product “illegal mass compounding and deceptive advertising” and warned of significant patient safety risks. Hims & Hers CEO Andrew Dudum said the company is committed to providing safe options and that it will continue to work with regulators to ensure patient safety.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.